Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Cancer
    March 2026

  1. Correction to "Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia".
    Cancer. 2026;132:e70347.
    >> Share


  2. Correction to "Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia".
    Cancer. 2026;132:e70325.
    >> Share

  3. LAWRENCE L
    Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
    Cancer. 2026;132:e70275.
    >> Share

    February 2026
  4. DINARDO CD, Croden J, Abdel-Salam HM, Kadia T, et al
    Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.
    Cancer. 2026;132:e70315.
    >> Share

  5. BUCHRITS S, Rozental A, Korngold N, Algor O, et al
    Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2026;132:e70265.
    >> Share

  6. IURLO A, Cattaneo D, Fava C, Castagnetti F, et al
    Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.
    Cancer. 2026;132:e70261.
    >> Share


  7. Correction to "Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: comparative analysis and usefulness of IGHV subset #2 to improve their accuracy".
    Cancer. 2026;132:e70302.
    >> Share

    January 2026

  8. Correction to "Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly".
    Cancer. 2026;132:e70232.
    >> Share

  9. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    >> Share

    December 2025
  10. ARGUELLO-TOMAS M, Lynton-Pons E, Albiol N, Lopez-Ferrer A, et al
    Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia.
    Cancer. 2025;131:e70216.
    >> Share

  11. SICURANZA A, Pacelli P, Santoni A, Raspadori D, et al
    Reply to "Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!".
    Cancer. 2025;131:e70214.
    >> Share

  12. OZDEMIR ZN, Eskazan AE
    Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!
    Cancer. 2025;131:e70215.
    >> Share

  13. FAN Z, Chen QW, Huang XY, Fu Q, et al
    Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.
    Cancer. 2025;131:e70225.
    >> Share

    November 2025
  14. BAO M, Zhang XS, Li ZR, Yu L, et al
    Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.
    Cancer. 2025;131:e70166.
    >> Share

  15. QIAN CS, Wang ZH, Li Z, Yao Z, et al
    A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leuk
    Cancer. 2025;131:e70168.
    >> Share

  16. OK CY, Natu A, Daneshpajouhnejad P, Fathalla LA, et al
    Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly.
    Cancer. 2025;131:e70176.
    >> Share

  17. KANTARJIAN HM, Borthakur G, Daver N, DiNardo C, et al
    A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens.
    Cancer. 2025;131:e70113.
    >> Share

  18. BARRIERE S, Bourgne C, Tassin T, Establie A, et al
    Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study.
    Cancer. 2025;131:e70140.
    >> Share

    October 2025
  19. SICURANZA A, Pacelli P, Santoni A, Abruzzese E, et al
    Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.
    Cancer. 2025;131:e70122.
    >> Share

  20. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    >> Share

    September 2025
  21. LIAN J, Zhuang X, Chen Y, Lin Q, et al
    Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2025;131:e70053.
    >> Share

  22. CAIROLI R, Del Castello L, Imbergamo S, Pierdomenico E, et al
    Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.
    Cancer. 2025;131:e70055.
    >> Share

    August 2025
  23. BURTON H, Boussi L, Nemirovsky D, Derkach A, et al
    Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.
    Cancer. 2025;131:e70024.
    >> Share

  24. SENAPATI J, Kantarjian HM, Kadia TM, Kekedjian J, et al
    Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.
    Cancer. 2025;131:e70028.
    >> Share

  25. WANG LL, Zhao P, Liu J, An ZY, et al
    Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.
    Cancer. 2025;131:e70044.
    >> Share

  26. ARORA S, Jen WY, Yilmaz M, Deshmukh I, et al
    Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
    Cancer. 2025;131:e70032.
    >> Share

  27. KAO HW, Chang H, Kuo MC, Wu JH, et al
    Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples.
    Cancer. 2025;131:e70048.
    >> Share

  28. QIAO C, Xia Y, Guo Z, Zhu L, et al
    Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases.
    Cancer. 2025;131:e70017.
    >> Share

    July 2025
  29. KANTARJIAN H, Breccia M, Haddad FG, Hehlmann R, et al
    Management of chronic myeloid leukemia in 2025.
    Cancer. 2025;131:e35953.
    >> Share

  30. BECKER PS
    Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.
    Cancer. 2025;131:e35973.
    >> Share

  31. WU Y, Yuan X, Lai X, Liu L, et al
    KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35941.
    >> Share

  32. BOYIADZIS M, Wei AH, Paiva B, Freeman SD, et al
    Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.
    Cancer. 2025;131:e35960.
    >> Share

  33. PATEL SA, Khedr S, Gordon CD, Nuvvula S, et al
    Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry.
    Cancer. 2025;131:e35950.
    >> Share

  34. GIAI V, Rosso T, Castagnetti F, Pregno P, et al
    Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.
    Cancer. 2025;131:e35963.
    >> Share

    May 2025
  35. KANTARJIAN H, Jain N, Litzow MR, Luger SM, et al
    The evolving therapeutic revolution in adult acute lymphoblastic leukemia.
    Cancer. 2025;131:e35872.
    >> Share

  36. ATALLAH E, Lipton JH
    Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived?
    Cancer. 2025;131:e35880.
    >> Share

  37. WINESTONE LE, Yang J, Banerjee T, Sangaramoorthy M, et al
    Impact of neighborhood archetypes on overall mortality among young patients with acute leukemia in California.
    Cancer. 2025;131:e35863.
    >> Share

    April 2025
  38. KANTARJIAN H, Zhai Y, Oehler VG, Jamy O, et al
    Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research.
    Cancer. 2025;131:e35832.
    >> Share

  39. THAKUR RK, Wang ES
    Top advances of the year: Acute myeloid leukemia.
    Cancer. 2025;131:e35834.
    >> Share

  40. GOULART H, Kantarjian H, Borthakur G, Daver N, et al
    Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
    Cancer. 2025;131:e35840.
    >> Share

  41. PETERS DT, Zeidner JF
    A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.
    Cancer. 2025;131:e35838.
    >> Share

  42. LEBER B, Ruiz MT, Elgendy H, Pettersson F, et al
    Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.
    Cancer. 2025;131:e35845.
    >> Share

  43. KHOURI MR, Wang B, Pearson LK, Gillis-Smith AJ, et al
    Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations.
    Cancer. 2025;131:e35846.
    >> Share

  44. SENAPATI J, Kadia TM, Daver NG, DiNardo CD, et al
    Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.
    Cancer. 2025;131:e35806.
    >> Share

  45. PAPAYANNIDIS C, Petracci E, Zappasodi P, Fracchiolla N, et al
    INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2025;131:e35820.
    >> Share

  46. NANNI J, Azzali I, Papayannidis C, Mule A, et al
    Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
    Cancer. 2025;131:e35824.
    >> Share

    March 2025

  47. Erratum to "Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study".
    Cancer. 2025;131:e35803.
    >> Share

  48. BAZINET A, Bataller A, Kadia T, Daver N, et al
    A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.
    Cancer. 2025;131:e35813.
    >> Share

  49. KUGLER E, Kantarjian H, Jabbour E, Khaire N, et al
    Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2025;131:e35773.
    >> Share

  50. BROWN JC, Ma C, Shi Q, Saltz LB, et al
    The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance).
    Cancer. 2025;131:e35727.
    >> Share

    February 2025
  51. LUSKIN MR, Yin J, Lozanski G, Curran E, et al
    Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
    Cancer. 2025;131:e35750.
    >> Share

  52. GYAN E, Minden MD, Kubo K, Rambaldi A, et al
    Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.
    Cancer. 2025;131:e35746.
    >> Share

  53. ESKAZAN AE
    Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
    Cancer. 2025;131:e35737.
    >> Share

    January 2025
  54. WANG L, Chen Y, Zang M, Zhou J, et al
    Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35717.
    >> Share

  55. LLORET-MADRID P, Boluda B, Martinez-Lopez J, Bergua J, et al
    Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
    Cancer. 2025;131:e35696.
    >> Share

  56. SASAKI K
    Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid).
    Cancer. 2025;131:e35704.
    >> Share

  57. ARGUELLO-TOMAS M, Mozas P, Albiol N, Lopez-Esteban M, et al
    Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.
    Cancer. 2025;131:e35552.
    >> Share

    November 2024
  58. YU L, Li W, Xu N, Liu X, et al
    Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.
    Cancer. 2024 Nov 26. doi: 10.1002/cncr.35652.
    >> Share

  59. JEN WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, et al
    Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
    Cancer. 2024 Nov 25. doi: 10.1002/cncr.35662.
    >> Share

  60. ZHANG C, Gu R, Wang H, Zhou C, et al
    Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35641.
    >> Share

  61. OKADA Y, Tachi N, Shimazu Y, Murata M, et al
    Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35627.
    >> Share

  62. NIERENGARTEN MB
    Blinatumomab approved as consolidation therapy for MRD-negative B-cell precursor acute lymphoblastic leukemia.
    Cancer. 2024;130:3622.
    >> Share

  63. NIERENGARTEN MB
    New predictive model for treatment failure in chronic myeloid leukemia.
    Cancer. 2024;130:3621.
    >> Share

  64. HOANG TT, Rathod RA, Rosales O, Castellanos MI, et al
    Residential proximity to oil and gas developments and childhood cancer survival.
    Cancer. 2024;130:3724-3733.
    >> Share

    October 2024
  65. RODRIGUEZ-ARBOLI E, Rodriguez-Veiga R, Soria-Saldise E, Bergua JM, et al
    A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618.
    >> Share

  66. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    >> Share

  67. NIERENGARTEN MB
    Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
    Cancer. 2024;130:3237.
    >> Share

    September 2024
  68. LI Z, Zhang X, Zhao Y, Lu L, et al
    Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.
    Cancer. 2024 Sep 21. doi: 10.1002/cncr.35565.
    >> Share

    August 2024
  69. ZHANG X, Wang Y, Tian X, Sun L, et al
    Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective multicenter study.
    Cancer. 2024 Aug 13. doi: 10.1002/cncr.35481.
    >> Share

  70. KANTARJIAN HM, Boissel N, Papayannidis C, Luskin MR, et al
    Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Cancer. 2024 Aug 2. doi: 10.1002/cncr.35505.
    >> Share

    July 2024
  71. JEN WY, Konopleva M, Pemmaraju N
    Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Cancer. 2024;130:2260-2271.
    >> Share

    June 2024
  72. LABRADOR J, Martinez-Cuadron D, Boluda B, Serrano J, et al
    Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
    Cancer. 2024 Jun 19. doi: 10.1002/cncr.35431.
    >> Share

    May 2024
  73. SENAPATI J, Kantarjian HM, Bazinet A, Reville P, et al
    Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35388.
    >> Share

  74. HADDAD FG, Sasaki K, Nasr L, Short NJ, et al
    Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35384.
    >> Share

  75. BAZARBACHI AH, Labopin M, Raiola AM, Blaise D, et al
    Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Tran
    Cancer. 2024 May 17. doi: 10.1002/cncr.35365.
    >> Share

    April 2024
  76. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
    Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
    >> Share

  77. LOKE J, Labopin M, Craddock C, Socie G, et al
    Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
    Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
    >> Share

  78. WANG X, Zhang B, Zhang Q, Zhou H, et al
    Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
    >> Share

    March 2024
  79. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
    Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
    Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
    >> Share

  80. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    >> Share

  81. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    >> Share

    February 2024
  82. DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al
    Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251.
    >> Share

  83. GUAN F, Yang L, Chen Y, Shi J, et al
    Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
    >> Share

    January 2024
  84. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    >> Share

    December 2023
  85. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    >> Share

    November 2023
  86. YANG X, Yang L, Luo A, Liu S, et al
    IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129.
    >> Share

  87. RUIZ J, Li Y, Cao L, Huang YV, et al
    Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109.
    >> Share

  88. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    >> Share

  89. GUPTA DG, Varma N, Sharma P, Truica MI, et al
    Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Cancer. 2023;129:3390-3404.
    >> Share

    October 2023
  90. PULLARKAT V, Chen LS, Palmer J, Zhang J, et al
    A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077.
    >> Share

  91. GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al
    A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051.
    >> Share

  92. EFFICACE F, Cottone F, Yanez B, Kota V, et al
    Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
    Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021.
    >> Share

    September 2023
  93. SASAKI K, Haddad FG, Short NJ, Jain N, et al
    Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
    Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038.
    >> Share

  94. GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al
    Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016